Business Wire

LR Health & Beauty Strengthens Its Management Team With Martin Lipp as New Chief Financial Officer (CFO)

7.9.2026 15:36:00 CEST | Business Wire | Press Release

Share

The LR Health & Beauty GmbH, Europe’s leading social commerce company for high-quality nutritional supplements and beauty products, is strengthening its management team: effective 7 September 2026, Martin Lipp takes over as Chief Financial Officer (CFO) and joins the Executive Management Team. In his new role, Martin Lipp will be responsible for Global Controlling & Finance, Legal, IT and Operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260907262360/en/

Martin Lipp, new CFO of the LR Group

“With Martin Lipp, we are gaining a highly experienced international finance executive with extensive expertise in managing and transforming businesses. During the current transition phase, he will enrich the senior management in particular with his strong transformation expertise and excellent know-how in the areas of finance, operations and IT. Together, we will consistently drive forward the implementation of our strategy with a clear focus on profitability, efficiency and sustainable growth,” says Jörg Körfer, CEO of the LR Group.

Martin Lipp brings around 20 years of leadership experience in international companies across three continents. Throughout his career, he has led finance organisations in the healthcare, consumer goods, automotive and renewable energy sectors. Most recently, he served as CFO of the Brazilian Correias Mercúrio Group. Prior to this, as CFO of the Schletter Solar Group, an international provider of solar mounting systems, he successfully guided the company through a period of restructuring and transformation and supported its subsequent change of ownership. He has also held senior finance positions at McKesson and Benteler Automotive.

“I am very much looking forward to my new role at LR and the trust placed in me. The company has a strong brand and an attractive business model, which I see as offering significant potential. Together with the management team and our employees, I want to contribute to returning the LR Group to a path of sustainable and profitable growth,” says Martin Lipp, new CFO of the LR Group.

LR Group

Operating under the guiding principle “More quality for your life”, the LR Group, headquartered in Ahlen, Westphalia, successfully produces and distributes a range of high-quality nutritional supplements and cosmetics in 32 countries. As an attractive social commerce company, LR supports personal interaction within its community with efficient digital solutions.

Since 1985, LR has been firmly established in the market as a “people business”, where people and personal advice take centre stage. In an era of changing working environments, the business model particularly appeals to those seeking greater flexibility, a better work–life balance and increased financial independence.

Processing Aloe Vera has been one of LR’s core competencies for over 20 years. Only the valuable inner leaf is used for its products. In Ahlen, the company has built one of Europe’s most modern Aloe Vera production facilities for Aloe Vera drinking gels.

In autumn 2009, LR founded the LR Global Kids Fund e.V., which works with local institutions to provide efficient, unbureaucratic support for disadvantaged children and their families in many countries around the world. For further information on our commitment to sustainability, please see our Sustainability Report.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260907262360/en/

Contacts

Public Relations:
LR Global Holding
Almut Kellermeyer
Head of Corporate Communication
Kruppstraße 55
59227 Ahlen
Phone.: 02382 7658-106
E-Mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fir.lrworld.com
%2F&esheet=54599512&newsitemid=20260907262360&lan=en-US&anchor=https%3A%2F%2Fir.
lrworld.com%2F&index=2&md5=219696121eb087c6e7d046d10210c1fb

IR Contact:
cometis AG
Thorben Burbach
Friedrichstraße 22
65185 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye